List of Excipients in Branded Drug ZYRTEC HIVES

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Kenvue Brands LLC	ZYRTEC HIVES	cetirizine hydrochloride	50580-116	CELLULOSE, MICROCRYSTALLINE
Kenvue Brands LLC	ZYRTEC HIVES	cetirizine hydrochloride	50580-116	CROSCARMELLOSE SODIUM
Kenvue Brands LLC	ZYRTEC HIVES	cetirizine hydrochloride	50580-116	HYPROMELLOSES
Kenvue Brands LLC	ZYRTEC HIVES	cetirizine hydrochloride	50580-116	LACTOSE MONOHYDRATE

ZYRTEC Hives Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

ZYRTEC Hives is an OTC cetirizine product positioned for temporary relief of hives and itching associated with urticaria. Its commercial value comes from brand recognition, rapid once-daily dosing, dosage-form breadth, and consumer trust rather than active-ingredient exclusivity. Cetirizine is a mature small-molecule antihistamine with no biosimilar risk and limited meaningful patent protection. The strongest commercial opportunities are differentiated formulations, pediatric and dysphagia-friendly delivery systems, allergen-conscious excipient profiles, and private-label or co-development partnerships.

What is ZYRTEC Hives and what active ingredient does it contain?

ZYRTEC Hives contains cetirizine hydrochloride, a second-generation H1 antihistamine. The standard adult dose is 10 mg once daily. The product is marketed for temporary relief of hives and itching, alongside allergic rhinitis symptoms such as sneezing, runny nose, itchy or watery eyes, and itchy nose or throat.[1]

Attribute	ZYRTEC Hives profile
Active ingredient	Cetirizine hydrochloride
Therapeutic class	Second-generation H1 antihistamine
Primary OTC use	Hives, itching, and allergy symptoms
Standard adult strength	10 mg
Typical frequency	Once daily
Regulatory status	FDA OTC product
Product category	Small-molecule pharmaceutical
Biosimilar exposure	None
Main commercial competitors	Claritin, Allegra, Benadryl, store brands
Primary formulation opportunity	Consumer-friendly delivery and excipient differentiation

The product is generally associated with the ZYRTEC Allergy brand. "ZYRTEC Hives" is a use-positioning concept within the broader cetirizine product family rather than a biologic or separately protected molecular entity.

What excipients are used in ZYRTEC Hives formulations?

The excipients vary by dosage form and manufacturer. The tablet, chewable tablet, orally disintegrating tablet, syrup, and generic equivalents do not use identical inactive ingredients.

Conventional 10 mg tablets

A conventional cetirizine tablet commonly uses:

• Lactose monohydrate or another diluent
• Microcrystalline cellulose as a compression aid
• Colloidal silicon dioxide as a glidant
• Magnesium stearate as a lubricant
• Hypromellose as a film-coating polymer
• Polyethylene glycol in the coating system
• Titanium dioxide or another opacifier and colorant

The exact composition depends on the approved manufacturer and product code. FDA labeling should control any formulation comparison because inactive ingredients can differ among branded, authorized generic, and ANDA products.[1,2]

Chewable tablets

Chewable cetirizine products typically require a different excipient platform. Relevant functions include:

• Mannitol or another low-moisture, pleasant-tasting filler
• Microcrystalline cellulose or a compressible cellulose derivative
• Povidone or another binder
• Magnesium stearate
• Flavoring agents
• Sweeteners such as sucralose or acesulfame potassium
• Colorants where permitted

The main development challenge is balancing taste masking, hardness, rapid disintegration, and low friability. Cetirizine has a noticeable active-ingredient taste in oral products, so flavor and sweetener selection can materially affect consumer acceptance.

Oral solution or syrup

Liquid products generally use a water-based system with a combination of:

• Purified water
• Sorbitol solution or another bulk sweetener
• Glycerin or propylene glycol as a humectant and cosolvent
• Buffering agents
• Flavor
• Preservative, if required by the formulation
• High-intensity sweetener

The preservative system must be evaluated against pH, microbial challenge results, packaging, and intended shelf life. Sorbitol-based systems can create gastrointestinal tolerability concerns in sensitive consumers, while sugar-free positioning can create a stronger need for taste optimization.

How important are excipients to the ZYRTEC Hives commercial strategy?

Excipients are commercially important because cetirizine itself is commoditized. A new product cannot usually command a premium merely by containing cetirizine. The value must come from an improved consumer experience or a differentiated use case.

The most defensible excipient-led claims are usually tied to measurable product attributes:

• Faster disintegration
• Improved taste
• Sugar-free formulation
• Reduced tablet size
• Better swallowability
• Improved moisture resistance
• Lower allergen burden
• Pediatric acceptability
• Reduced use of artificial colors
• Compatibility with unit-dose packaging
• Stable liquid formulation without excessive preservative load

A formulation must avoid implying that an excipient makes cetirizine more clinically effective unless that claim is supported by appropriate clinical and regulatory evidence. Excipients can support delivery and adherence claims, but they do not automatically create a new therapeutic indication.

What formulation opportunities exist for ZYRTEC Hives?

Orally disintegrating and fast-dissolving tablets

A fast-dissolving tablet could target consumers who have difficulty swallowing conventional tablets or who want medication without water. Candidate excipient systems include crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, mannitol, and spray-dried co-processed excipients.

The principal development risks are:

• Bitter taste exposure before swallowing
• Friability during transport
• Sensitivity to humidity
• Packaging cost
• Dose uniformity at low tablet mass
• Need for robust moisture-barrier packaging

A strong product would combine rapid disintegration with effective taste masking. A fast-disintegrating tablet that leaves a bitter residue may underperform a conventional tablet despite better laboratory disintegration time.

Chewable tablets for pediatric and family use

Chewables are commercially attractive because parents often prefer a dosage form that avoids liquid measuring devices. The formulation should prioritize:

• Low aftertaste
• Small tablet size
• Consistent texture
• Low sugar or sugar-free positioning
• Limited dental-health concerns
• Packaging that prevents accidental pediatric access

A pediatric opportunity must remain consistent with FDA age labeling and dosing instructions. The excipient profile should also account for children with food allergies, metabolic disorders, or intolerance to specific sweeteners.

Sugar-free oral solution

A sugar-free cetirizine liquid can target families, older adults, and consumers with dietary restrictions. Sorbitol, glycerin, and high-intensity sweeteners are common design tools, but the combination can produce lingering sweetness or gastrointestinal complaints.

Commercial differentiation may come from:

• Better flavor masking
• Lower viscosity
• Smaller dosing volume
• Clear dosing syringe compatibility
• Alcohol-free positioning
• Reduced artificial-color use
• Preservative-minimized packaging

Unit-dose stick packs or premeasured liquid sachets could support travel and convenience, although packaging cost and stability data would determine commercial viability.

Liquid-filled capsules and softgels

A liquid-filled capsule could offer a smaller or easier-to-swallow presentation, but the economic case is less clear for a low-cost antihistamine. The product would need a clear consumer benefit, such as reduced tablet size, improved swallowability, or premium packaging.

Liquid-filled systems also create additional development work involving:

• Cetirizine solubility
• Capsule-shell compatibility
• Fill migration
• Moisture transfer
• Oxidative and hydrolytic stability
• Manufacturing scale-up

Excipient-minimized products

A "simple ingredients" or "excipient-conscious" product could target consumers seeking fewer colors, fewer preservatives, or avoidance of lactose. This strategy is most credible when the labeling clearly identifies the excluded excipients and explains the relevant consumer benefit without making unsupported safety claims.

Possible positioning includes:

• Lactose-free
• Dye-free
• Alcohol-free liquid
• Artificial-flavor-free
• Preservative-free, where packaging and stability permit
• Gluten-free, if substantiated under applicable FDA requirements

These claims can increase the addressable market, but they also narrow formulation flexibility and may increase manufacturing cost.

What patents protect ZYRTEC Hives formulations?

The original cetirizine compound and early product patents are no longer the principal barrier to entry. Cetirizine is a mature active ingredient, and generic versions have been widely available for years.

For current commercial planning, protection is more likely to arise from:

1. Formulation patents covering a specific excipient combination or release profile.
2. Taste-masking patents covering polymer, lipid, ion-exchange, or multiparticulate systems.
3. Orally disintegrating dosage-form patents.
4. Packaging patents involving moisture protection or unit-dose delivery.
5. Method-of-use patents, although OTC antihistamine use claims are difficult to differentiate broadly.
6. Trademark and trade-dress rights associated with ZYRTEC branding.

The relevant patent estate should be assessed at the specific product and jurisdiction level. A formulation patent must be mapped against the actual inactive ingredients, manufacturing process, dissolution profile, and claim limitations. A generic competitor can often avoid infringement by changing the excipient system while retaining the same cetirizine strength.

Is ZYRTEC Hives listed in the Orange Book?

ZYRTEC Hives is an OTC product, and ordinary OTC products are not analyzed in the same manner as an actively listed prescription NDA with a current Orange Book patent block. FDA's Orange Book primarily supports approved prescription drug and certain other application-based products, including patent and exclusivity information for eligible applications.[3]

The commercial implication is important: a competing cetirizine product generally does not face the same Orange Book patent certification framework that governs a patented prescription drug. Brand protection therefore depends more heavily on trademark, distribution, consumer loyalty, regulatory compliance, and formulation differentiation.

When does ZYRTEC Hives lose exclusivity?

ZYRTEC's molecule-level exclusivity has already expired. The product has no meaningful remaining new-chemical-entity exclusivity. Its market position is protected primarily by:

• Brand equity
• Retail placement
• National advertising
• Product-line breadth
• Consumer familiarity
• Formulation and packaging execution
• Trademark rights

The original prescription-era cetirizine development involved UCB and later commercial partners, but the current OTC market is dominated by brand and generic competition rather than patent exclusivity. Kenvue markets ZYRTEC as part of its self-care portfolio following the separation of its consumer-health business from Johnson & Johnson.[4]

What Paragraph IV challenges and generic entry risks exist?

Paragraph IV litigation is not the central risk for the current OTC ZYRTEC Hives business. For a mature OTC cetirizine product, the principal entry risks are:

• Store-brand cetirizine tablets
• Retailer-owned chewables
• Private-label liquids
• E-commerce products
• Authorized or licensed brand alternatives
• Reformulated products using the same active ingredient

Generic entry can occur through the applicable FDA OTC pathway, including products conforming to an OTC monograph where the product falls within monograph conditions. Cetirizine is also available through approved drug applications and established generic channels.[3,5]

The strongest competitive threat is private-label substitution. Consumers may accept a store-brand cetirizine product when the dose, tablet appearance, and dosing frequency are familiar. Brand premium therefore depends on perceived reliability, packaging, availability, and a differentiated dosage form.

Which companies challenge ZYRTEC Hives commercially?

The key competing brands are:

Brand	Active ingredient	Main commercial angle
ZYRTEC	Cetirizine	Fast allergy and hives relief, strong brand recognition
Claritin	Loratadine	Once-daily, non-drowsy positioning
Allegra	Fexofenadine	Non-drowsy positioning and broad allergy portfolio
Benadryl	Diphenhydramine	Longstanding allergy and itching brand, greater sedation concern
Store brands	Cetirizine, loratadine, fexofenadine, others	Lower price and retailer access

Cetirizine competes directly with loratadine and fexofenadine for daily allergy use. For hives, the competitive set also includes physician-directed antihistamine regimens and prescription therapies for chronic spontaneous urticaria. ZYRTEC Hives occupies the OTC self-care segment and does not compete directly with biologics such as omalizumab on equivalent regulatory or clinical positioning.

What biosimilar risk affects ZYRTEC Hives?

There is no biosimilar risk because cetirizine is a chemically synthesized small molecule, not a biologic. The relevant risks are generic substitution and formulation replication.

The absence of biosimilar risk simplifies the competitive analysis, but it does not reduce price pressure. Small-molecule antihistamines generally face rapid commoditization once formulation and brand barriers weaken.

What manufacturing and IP barriers matter for cetirizine products?

Manufacturing barriers are moderate rather than high. Standard tablets and liquids can be produced by many contract manufacturers. The more defensible barriers are technical and operational:

• Taste-masking process know-how
• Low-dose content uniformity
• Moisture-controlled manufacturing
• Robust orally disintegrating tablet compression
• Preservative-free liquid stability
• High-barrier blister or sachet packaging
• Child-resistant and senior-friendly package design
• Validated cleaning procedures for potent flavor or color systems
• Scalable coating and granulation processes

Manufacturing know-how can create practical advantage even where patent protection is weak. Trade secrets are most relevant for flavor systems, granulation parameters, coating conditions, and packaging combinations that improve shelf life or consumer experience.

How should a company prioritize an excipient investment?

A commercially rational development sequence is:

Priority	Product concept	Commercial rationale	Main risk
1	Taste-masked chewable	Family and pediatric convenience	Taste failure or high manufacturing cost
2	Fast-dissolving tablet	Water-free use and swallowability	Moisture sensitivity and friability
3	Sugar-free liquid	Pediatric and dietary positioning	Preservative and stability burden
4	Dye-free or lactose-free tablet	Excipient-conscious consumers	Limited willingness to pay
5	Premium softgel	Differentiated swallowability	Weak cost-benefit case
6	Unit-dose liquid or powder	Travel and adherence convenience	Packaging economics

The best near-term opportunity is usually a dosage form with a clear consumer benefit and a manageable regulatory path. A taste-masked chewable or moisture-stable orally disintegrating tablet offers more differentiation than a conventional tablet with a minor excipient substitution.

What regulatory pathway applies to a new ZYRTEC Hives formulation?

A company developing a new cetirizine OTC product must determine whether the product fits the applicable FDA OTC monograph conditions or requires an approved drug application. The regulatory pathway depends on dosage form, strength, labeling, active ingredient, excipient system, and intended claims.[5]

Key regulatory controls include:

• Active ingredient identity and strength
• Labeling for hives and allergy symptoms
• Age restrictions and dosing
• Inactive-ingredient safety
• Stability and shelf-life data
• Microbiological quality for liquids
• Container-closure performance
• Child-resistant packaging where required
• Tamper-evident packaging
• Manufacturing under current good manufacturing practice

A novel excipient, unusual delivery system, or claim outside the established OTC framework may increase regulatory burden. Excipient novelty is not a substitute for an appropriate FDA pathway.

What licensing and commercial partnership opportunities exist?

The main licensing opportunities are formulation and platform transactions rather than rights to cetirizine itself. Potential counterparties include:

• Consumer-health companies seeking OTC line extensions
• Contract development and manufacturing organizations
• Flavor and taste-masking technology providers
• Oral thin-film and orally disintegrating tablet developers
• Retailers seeking differentiated private-label products
• International distributors with regional OTC registrations

A platform owner could license a taste-masking technology across cetirizine, loratadine, fexofenadine, and pediatric analgesic products. That structure may produce greater value than a single-product license because the same excipient and manufacturing platform can support multiple OTC indications.

The strongest deal terms would likely focus on territory, dosage form, manufacturing rights, minimum volumes, regulatory responsibilities, and ownership of formulation improvements. Royalty economics would be constrained by the low price of generic cetirizine unless the product carries a premium consumer proposition.

What is the revenue exposure for Kenvue and ZYRTEC?

Kenvue reports ZYRTEC within its self-care portfolio rather than providing a standalone public revenue line in its principal reporting disclosures.[4] This limits precise public measurement of ZYRTEC Hives revenue exposure.

Commercial exposure is still material at the brand level because ZYRTEC contributes to:

• Allergy-season revenue
• OTC pharmacy and mass-retail distribution
• Cross-selling across allergy products
• Consumer recognition in hives and itching relief
• Retail shelf space and digital search visibility

Revenue sensitivity is likely driven by allergy-season intensity, retailer inventory, promotional spending, store-brand substitution, pricing, and new dosage-form launches. A successful excipient-led extension could protect revenue by moving the brand away from direct tablet-price comparison.

How strong is the ZYRTEC Hives patent estate?

The patent estate is weak as a molecule-level barrier and potentially moderate for a genuinely differentiated formulation. Strength depends on whether a patent claim covers a commercially necessary feature that competitors cannot easily design around.

Protection category	Current strategic strength
Cetirizine molecule	Low
Standard 10 mg tablet	Low
Basic liquid formulation	Low to moderate
Taste-masked chewable	Moderate if claims are technically narrow but difficult to replicate
Orally disintegrating tablet	Moderate, subject to prior art and design-around risk
Packaging configuration	Low to moderate
Trademark and trade dress	Moderate to strong for brand recognition
Manufacturing know-how	Moderate if process parameters are difficult to reproduce

A formulation patent is strongest when it links a defined excipient architecture to a measurable technical result, such as reduced bitterness, improved stability, or controlled disintegration. Broad claims covering routine excipient substitutions face substantial validity and design-around risk.

Key Takeaways

• ZYRTEC Hives is an OTC cetirizine product whose commercial strength comes from branding and dosage-form execution, not current molecule-level exclusivity.
• Excipients can support premium positioning through taste masking, rapid disintegration, sugar-free delivery, dye-free labeling, lactose avoidance, and improved swallowability.
• The highest-value opportunities are likely chewables, orally disintegrating tablets, and improved pediatric liquids.
• Generic and store-brand substitution represent greater risks than Paragraph IV litigation or biosimilar competition.
• Kenvue does not publicly disclose standalone ZYRTEC Hives revenue in its principal filings.
• Formulation patents can provide moderate protection, but conventional cetirizine tablets and liquids are readily exposed to design-around strategies.
• Licensing value is strongest for reusable taste-masking, oral-disintegration, packaging, or pediatric-delivery platforms.

FAQs

Can ZYRTEC Hives be reformulated without changing the active ingredient?

Yes. A company can retain cetirizine hydrochloride while changing excipients, dosage form, flavor, coating, packaging, or release characteristics, subject to FDA requirements and applicable intellectual-property constraints.

Is lactose avoidance a meaningful opportunity in cetirizine products?

It can be. Lactose-free positioning may appeal to consumers who avoid lactose or prefer simplified inactive-ingredient labeling, but it is unlikely to support a substantial premium without a broader benefit such as chewability or improved tolerability.

Which excipient is best for masking cetirizine bitterness?

No single excipient is universally optimal. Effective systems often combine sweeteners, flavors, polymeric coating, ion-exchange technology, or multiparticulate encapsulation. Performance depends on dosage form, dissolution target, and bitterness exposure time.

Can a cetirizine chewable obtain new patent protection?

Yes, if the formulation has patentable technical features. A patent may cover a specific taste-masking system, excipient ratio, particle architecture, manufacturing process, or stability result. Routine substitution of one filler or sweetener for another is less likely to support durable protection.

Does ZYRTEC Hives have biologic or biosimilar competition?

No. Cetirizine is a small-molecule drug. Competition comes from generic cetirizine products and other antihistamines, not biosimilars.

References

1. DailyMed. (n.d.). Zyrtec allergy cetirizine hydrochloride tablet, film coated: Drug label. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. DailyMed. (n.d.). Cetirizine hydrochloride oral solution and chewable tablet labels. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. Kenvue Inc. (2024). Annual report for the fiscal year ended December 31, 2023. https://www.kenvue.com/investors

5. U.S. Food and Drug Administration. (n.d.). Over-the-counter monograph drugs. https://www.fda.gov/drugs/over-counter-otc-nonprescription-medicines/otc-monograph-drugs